2024 A Focus on Intratumoral Therapies, Vaccines, & Cytokines

aci-intratumoral-therapies_-_Edited.png

Wednesday, Oct. 9, 2024 | 11a.m.-3 P.M. ET
live via zoom webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of intratumoral therapies, vaccines, & cytokines. FREE for healthcare professionals, students, patients and patient advocates.

New for 2024

  • Session on in situ delivery of therapies (title TBD)
  • Session on emerging therapies, where the EMERALD trial and FLASH radiotherapy plan to be discussed
  • FDA approval of a new cytokine-based therapy is expected to occur in Q1 2024, and this will be addressed if approval occurs
The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Wil Ngwa, PhD, MSc
Johns Hopkins University

Mark P. Rubinstein, PhD
The Ohio State University

Lei Zheng, MD, PhD
Johns Hopkins University

Program Snapshot

Credits Available
Physician Education: Credit being determined
Pharmacy Education: Credit being determined
Nursing Education: Credit being determined

Program Date & Location

Wednesday, Oct. 9, 2024 at 11 a.m.-3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Intratumoral Therapies, Vaccines, & Cytokines >

Program Agenda

11–11:05 a.m.

 

Welcome and Relevant SITC Resources

11:05-11:20 a.m.

   Background on IL-15 and Cytokines 
Mark Rubinstein, PhD – The Ohio State University

11:20–11:35 a.m.

 

Cytokines

11:35 a.m.–12:05 p.m.

 

Vaccines, Neoantigen Vaccinations, Vaccines in Clinical Development 
Kevin Soares, MD, MSc – Memorial Sloan Kettering Cancer Center

12:05-12:35 p.m.

 

In Situ Delivery of Treatments
Sandra Demaria, MD – Weill Cornell Medical College

12:35–1:05 p.m.

 

Emerging Areas: EMERALD Trial, FLASH Radiotherapy
Sandra Demaria, MD – Weill Cornell Medical College

1:05–1:20 p.m.

 

Break 

1:20–2 p.m

 

Cancer Immunotherapy in Practice

Jordan McPherson, PharmD, MS, BCOP – University of Utah School of Medicine

2–3 p.m

 

Faculty Panel

    3 p.m

     

    Closing Remarks

      SITC ACI Series

      This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.

      Program Details

      Target Audience

      The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

      Case Study Submission Information

      As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

      Program Learning Objectives

      • Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.

      • Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.

      • Outline common toxicities with intratumoral therapies, vaccines and cytokines and their management.

      Accreditation Information

      Joint Accreditation Statement

      thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

      This activity is approved for AMA PRA Category 1 Credits™, ABIM MOC credit, ANCC and ACPE contact hours.

      Disclosures

      Disclosure of Conflicts of Interest

      PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

      Avoid Fraudulent ACI Websites

      Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

      All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.